



THE BIOVAC INSTITUTE

The science of protecting life

AVMI

AGM meeting



30 November 2016

Cape Town, S.A.

Key take home messages



1. Biovac progress and achievements wrt 4 key areas:

- Infrastructure
- Vaccine manufacturing qualified staff
- Technology transfers
- Demonstrated globally recognized product development capacity

Biovac Achievements: Infrastructure



Investment in infrastructure: 2007



Investment in infrastructure: 2012




Virtual site tour

Building I
Cold room
storage

Building C
Aseptic vial
manufacturing facility

Building A
QC Labs



Building C1
Visual
inspection,
Labelling &
Packaging

Building C
API
manufacturing facility

Building C1
Aseptic pre-filled syringe
manufacturing facility

Virtual site tour

Black and Clean Utilities



Virtual site tour

Cleaning and Preparation



Virtual site tour

Fermentation



Virtual site tour

Purification



Virtual site tour

Filling



Virtual site tour

Filling (2)



Virtual site tour

Inspection and Labelling




Biovac Achievements: Qualified Staff



~ 200 qualified staff in vaccine manufacturing

Headcount Growth 2003 to 2016



Biovac Achievements: Tech transfers



- **MULTINATIONAL TECHNOLOGY TRANSFERS**
 - **Hexaxim (Sanofi)**
 - Filling
 - Multi-product vial filling line
 - **Prevnar (Pfizer)**
 - Formulation & filling
 - Dedicated formulation suite
 - Multi-product pre-filled syringe (PFS) filling line
 - Automated PFS viewing, labelling & packaging


Biovac Achievements: PD capacity



Demonstrated globally recognized product development capacity

- **DEVELOPED CONJUGATE HIB VACCINE TECHNOLOGY**
 - **out-licensed to 2 Asian vaccine manufacturers**
- **GLOBAL PARTNERSHIPS:**
 - **PATH pneumococcal conjugate vaccine project**
 - Chengdu Institute for Biological Products
 - **ISS/Diatheva recombinant protein demonstration runs for an HIV vaccine target**
 - **PATH Group B streptococcus conjugate vaccine project**
 - Inventprise

In summary



THANK YOU

